New Zealand Government Reverses Groundbreaking Anti-Smoking Legislation for Economic Reasons

Regulations by 2FIRSTS.ai
Nov.29.2023
New Zealand Government Reverses Groundbreaking Anti-Smoking Legislation for Economic Reasons
New Zealand's landmark smoking ban law, aimed at achieving a "smoke-free generation," has been repealed by the new government.

According to a report by Hipertextual, former New Zealand Prime Minister Jacinda Ardern announced a groundbreaking tobacco control law in 2021, with the aim of achieving a "smoke-free generation" and saving thousands of lives. The law received widespread support from health legislators around the world, with several countries announcing plans to follow suit. However, the new government in New Zealand repealed the law before it could be enacted, and openly admitted that the decision was driven by economic interests.

 

New Zealand's smoking ban bill aims to achieve its goals by gradually increasing the legal smoking age. Currently, in New Zealand and many other countries, the legal age for smoking is 18. The initial plan is to raise the age to 19 by 2026, followed by an annual increase of one year thereafter. Eventually, teenagers will no longer be permitted to smoke. Despite potentially appearing strict, this regulation is expected to save millions of lives and cost millions of dollars in healthcare expenses.

 

However, in the election, the newly elected government in New Zealand has promised to implement a historic tax reduction, which requires a complete overhaul. Given that the tobacco industry brings in a significant amount of revenue for the government, the newly elected right-wing coalition government wasted no time in making this decision.

 

Newly-appointed Minister of Finance, Nicola Willis, has announced the repeal of the smoking ban bill. This decision, driven by economic factors, did not originate from the Health Ministry. The tobacco industry contributes approximately $2 billion in tax revenue to the New Zealand government annually, making it an effective avenue for offsetting tax deductions.

 

A recent study suggests that Ardern's smoking ban bill could save $1.3 billion in healthcare costs over the next 20 years. However, this does not offset the profits from tobacco sales, thus making it an insufficiently compelling reason for the new government.

 

Furthermore, the World Health Organization (WHO) stated in its tobacco report that approximately 8 million people die each year globally due to smoking-related causes. Out of this number, 7 million people die directly from smoking, while the remaining 1 million are second-hand smoke inhalers. These individuals do not willingly smoke, yet they tragically lose their lives due to exposure to cigarette smoke.

 

Achieving a smoke-free generation is just one of the many proposed measures by the World Health Organization to prevent health issues caused by tobacco. Other measures include conducting health promotion campaigns to assist people in quitting smoking, issuing graphic health warnings, increasing taxes on tobacco companies, and regulating nicotine-containing products such as e-cigarettes.

 

At the beginning of this year, the Director-General of the organization, Tedros Adhanom Ghebreyesus, stated that only four countries in the world have implemented a comprehensive set of measures following most of the organization's recommendations. These countries include Brazil, Mauritius, Turkey, and the Netherlands. Among the member states of the European Union, only the Netherlands has achieved this feat. However, data shows that approximately 18.4% of the population aged 15 and above reported being daily smokers in 2019. The highest smoking rate was recorded in Bulgaria at 28.7%, while Sweden had the lowest at 6.4%.

 

Fortunately, several countries, such as Portugal, have started implementing the smoking ban law repealed by New Zealand and have also set goals to achieve a smoke-free generation.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
Special Report | Altria Subsidiaries Sue FDA to Vacate 2021 PMTA Rule as Agency Moves to Speed Reviews
2Firsts reviewed the original federal court complaint filed by Altria subsidiaries Helix Innovations and NJOY on Sept. 2 challenging FDA’s 2021 PMTA rule. The lawsuit questions whether FDA’s review process complies with the Tobacco Control Act’s 180-day timeline, even as the agency moves to accelerate PMTA reviews and issues more marketing orders. Drawing on the complaint, FDA records, government audits and recent court rulings, 2Firsts examines the legal arguments, supporting evidence and potential implications for the U.S. tobacco review system.
Regulations
Sep.03
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Invests ₱2.1 Billion to Upgrade Batangas Manufacturing Hub, Adds First Southeast Asia DIET Facility
JTI Asia Manufacturing Corp. has invested ₱2.1 billion, or about $37 million, in its manufacturing site in Malvar, Batangas, Philippines, to expand tobacco-processing capabilities. About ₱1.9 billion is allocated to JTI's first Dry Ice Expanded Tobacco, or DIET, facility in Southeast Asia, while more than ₱177 million has been spent on expanding its Controlled Atmosphere treatment facility. The Batangas plant supplies the Philippine market and exports to 22 overseas markets, making it one of JTI's key manufacturing hubs in Asia.
Sep.24
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
The vaping rate among women aged 25 to 34 in Great Britain reached 18.3% in 2025, up from 13.7% in 2024 and 8.3% in 2020, according to data from the Office for National Statistics (ONS). The figure was the highest for this group since records began in 2014 and exceeded the 14.4% recorded among men of the same age. Adults aged 25 to 34 also overtook those aged 16 to 24 as the age group with the highest vaping prevalence. Overall, about 5.4 million adults in Great Britain used e-cigarettes in 2025, broadly unchanged from the previous year.
DATA
Oct.13
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia Brings in Deloitte to Support Illicit Tobacco and Vape Enforcement Across Data, Processes and Project Delivery
Australia’s Department of Home Affairs has hired Deloitte to provide data analytics, business-process, communications and project-delivery support to the Office of the Illicit Tobacco and E-Cigarette Commissioner. The government says Deloitte personnel do not provide policy advice to the Commissioner or the Australian government, with policy development and decision-making remaining with public officials. The arrangement has nevertheless drawn scrutiny because Deloitte has previously provided professional services to several tobacco and vaping companies.
Sep.03
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
U.S. Fifth Circuit Vacates NicQuid Vape MDO, Says FDA Comparative-Efficacy Standard Violated APA Procedures
According to VitalLaw on August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit vacated an FDA marketing denial order (MDO) against NicQuid LLC, ruling that the agency’s comparative-efficacy standard for electronic nicotine delivery system (ENDS) applications had become a substantive rule requiring notice-and-comment rulemaking under the Administrative Procedure Act (APA). The court did not reject FDA’s authority to compare the public health benefits and risks of flavored vapes, but held that the agency could not establish a broadly binding standard through informal adjudications. The case was remanded to FDA for further proceedings.
Aug.28